1. Zusammenfassung der Literatur

PPPD vs. Kausch-Whipple:
Niedergethmann M, Shang E, Farag Soliman M, Saar J, Berisha S, Willeke F, Post S. Early and enduring nutritional and functional results of pylorus preservation vs classic Whipple procedure for pancreatic cancer. Langenbecks Arch Surg. 2006;391(3):195-202
Gefäßresektion (Pfortader):
Hartel M, Niedergethmann M, Farag-Soliman M, Sturm JW, Trede M and Post S. Can extended resections of the pancreatic head for carcinoma be performed as a routine procedure? Eur J Surg 2002; 168 : 707-712
Octreotidgabe:
Li-Ling J, Irving M. Somatostatin and octreotide in the prevention of postoperative pancreatic complications and the treatment of enterocutaneous pancreatic fistulas: a systematic review of randomized controlled trials. Br J Surg 2001;88:190
Pankreato-jejunostomie vs. -gastrostomie:
Wente MN, Shrikhande SV, Müller MW, Diener MK, Seiler CM, Friess H, Büchler MW.Pancreaticojejunostomy versus pancreaticogastrostomy: systematic review and meta-analysis. Am J Surg. 2007 Feb;193(2):171-83
Management postoperativer Komplikationen:
Niedergethmann M, Farag-Soliman M, Post S. Postoperative complications of pancreatic cancer surgery. Minerva Chirurgica 2004; 59: 175-183
Langzeit-Outcome bei Pankreaskarzinom:
Richter A, Niedergethmann M, Hartel M, Sturm JW, Lorenz D, Trede M and Post S. Longterm results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head – a 25-year experience. World J Surg (2003) 27:324-329
Adjuvante Therapie:
Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA (2007) 297:267-277

2. Aktuell laufende Studien zu diesem Thema

Folgende Studien laufen derzeit zur adjuvanten Therapie:

Adjuvante Therapie des R0-resezierten Pankreaskarzinoms
www.conko-studien.de/studien/conko_005/
Additive Therapie beim R1-resezierten Pankreaskarzinom (CONKO 006)
www.conko-studien.de/studien/conko_006/